Cohance Lifesciences is an integrated pharmaceutical and specialty chemicals company operating through three segments: Pharma CDMO (small molecules, ADCs, oligonucleotides), API+ (APIs and formulations), and Specialty Chemicals (agrochemicals and performance materials). It sits in the value chain as a contract development and manufacturing partner and an API supplier to innovators and generics. In its niches, it holds leadership: eight of its top ten API molecules hold leadership positions, and it commands over 50% global share in certain innovator products. The competitive structure is consolidated in high-barrier segments like controlled substances and ADC payloads, with few credible global players. Margin quality is evidenced by FY26 adjusted EBITDA margin of 21% (24.6% standalone) despite a difficult year, and a gross margin of 70.8%. Q1 FY27 margin collapsed to 2.2% due to trough volumes and subsidiary losses, but this is cyclical, not structural.
The economics persist because of customer qualification cycles that take seven to ten years, regulatory constraints for controlled substances, and high switching costs once a plant is qualified. In ADC and oligonucleotide segments, capabilities are described as hard to replicate, with investments in cGMP facilities and payload platforms, and the market is welcoming alternatives to Chinese suppliers. The API+ business benefits from backward integration and cost competitiveness, leading to a reload conversion above 90% and customer stickiness. Specialty chemicals faces Chinese generic pressure, but the company is shifting to innovator-led programs and qualification campaigns. These barriers mean the current trough is temporary, and once destocking ends and new programs commercialize, revenue and margins should recover to prior levels and beyond.
The inflection is the destocking normalization and commercial scale-ups. Management guided Q1 FY27 as the lowest quarter, with sequential improvement in Q2 and year-on-year growth from the second half of FY27. By 18 to 24 months out, roughly mid-FY28 to mid-FY29, we expect: the two destocked molecules returning, with a restocking order providing delivery visibility for Q4 FY27 and FY28; two molecules moved to commercial supply with deliveries across Q2 and Q3 FY27 for six intermediates; and specialty chemicals growth returning in FY28 after a qualification year. The capex of nearly INR 3 billion in FY27, including a $10 million NJ Bio expansion and the cGMP oligonucleotide facility validation, will enable scaling. By then, NJ Bio and Sapala should be operating with higher utilization, and the Phase 3 pipeline of 10 programs will drive commercial launches. Management targets $1 billion sales by FY30, implying substantial growth from the current INR 15 billion annualized revenue base.
On earlier calls, management had guided FY26 as a growth year, but it delivered a decline, with nine-month FY26 revenue down 6.7% and Q3 EBITDA margin at 15.5%, attributing the miss to destocking and the Nacharam disruption. They now explicitly call Q1 FY27 the low point, and have held this revised guidance: Q2 stable, H2 growth. They have delivered on some fronts: four commercial orders for a newly commercialized product, a follow-on purchase order for Sapala, 2.5x revenue growth at Sapala, and 11 customer audits without critical findings. However, NJ Bio continued to lose INR 328 million in Q1, and the USFDA issued a Form 483 with five observations, none related to data integrity. Capital allocation is disciplined: net cash of INR 2,512 million, capex of INR 598 million in Q1, and no dilution. They have committed to a strategic blueprint by end FY27.
The quantified earnings path starts from Q1 FY27 adjusted EBITDA of INR 92 million (2.2% margin) and recovers through Q2 and H2, with FY27 margin expected closer to the previous year's 21%. Operating leverage from volume recovery and mix normalization, plus scaling of high-margin ADC and oligo businesses, should push margins above 21% in FY28. For this to hold, the restocking order must deliver as planned, the FDA observations must be resolved, and NJ Bio must reduce losses as revenue converts. The single most important watchpoint is the return of the two destocked molecules and the timing of their orders; any slippage from H2 FY27 would falsify the recovery thesis. The tension between Q1's weak numbers and management's confidence is resolved by the visible order book: four intermediate orders, the restocking order, and a doubled RFQ funnel with an expected 20% win rate.
companyname: Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) ticker: COHANCE sector: Pharmaceutical Contract Research, Development and Manufacturing Organization (CRDMO) Cohance Lifesciences is an integrated pharmaceutical contract research, development and manufacturing organization (CRDMO) built through a merger and a string of acquisitions. The current entity took shape when Suven Pharmaceuticals merged with Cohance Lifesciences, effective May 1, 2025, after the earlie...
Read the full report →capex, new product segment, order book surge
No guidance
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Cohance Lifesciences Limited and 4,900+ companies.
5-day free pass. No card required.